...
首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Development and characterization of GRGDSPC-modified poly(lactide-co-glycolide acid) porous microspheres incorporated with protein-loaded chitosan microspheres for bone tissue engineering
【24h】

Development and characterization of GRGDSPC-modified poly(lactide-co-glycolide acid) porous microspheres incorporated with protein-loaded chitosan microspheres for bone tissue engineering

机译:GRGDSPC改性的聚乳酸-乙交酯-乙交酯-酸)多孔微球的开发和表征,并结合了蛋白质负载的壳聚糖微球,用于骨组织工程

获取原文
获取原文并翻译 | 示例

摘要

Scaffolds that can achieve cell adhesion and controlled release of protein drugs are very promising in bone tissue engineering. Due to their biocompatibility and injectablity, poly(lactide-co-glycolide acid) (PLGA) porous microspheres (PLGA-pMS) present potential scaffolds in bone tissue engineering. However, their application is hampered by the burst release of protein drugs and hydrophobicity that leads to poorcell adhesion. To overcome these drawbacks, we developed novel PLGA-pMS by incorporating bovine serum albumin (BSA) loaded chitosan microspheres (CS-MS) in Gly-Arg-Gly-Asp-Ser-Pro-Cys (GRGDSPC) modified PLGA-pMS (CS-MS/PLGA-pMS). GRGDSPC was used to enhance the hydrophilicity and cell affinity of the porous microspheres. Results showed that PLGA-pMS had a size of 446.77± 19.46 μm, with an average surface pore size of 21.56 ± 3.02 μm, whereas CS-MS had a size of 15.98 ± 0.96 μm and 16.35 ± 0.38 μm (5% and 10% TPP-prepared CS-MS, respectively). A scanning electron microscope (SEM) and a confocal laser scanning microscope (CLSM) revealed that CS-MS were partly embedded in the PLGA matrices and the integrity of CS-MS was retained. Thermogravimetry analyzer (TGA) also demonstrated that CS-MS were incorporated into PLGA-pMS. The CS-MS/PLGA-pMS had a size of 454.02 ±16.09 μm, with a BSA encapsulation efficiency of 53.19 ± 1.67% and 62.16 ± 3.44% (5% and 10% TPP-prepared CSMS, respectively). CS-MS/PLGA-pMS exhibited a sustained FITC-BSA release for 28 days. Modification of GRGDSPC significantly improved adhesion of MG-63 cells on the porous microspheres. In conclusion, CS-MS/PLGA-pMS may act as potential bifunctional scaffolds for bone tissue engineering.
机译:可以实现细胞粘附和蛋白质药物控制释放的支架在骨组织工程中非常有前途。由于它们的生物相容性和可注射性,聚(丙交酯-共-乙交酯酸)(PLGA)多孔微球(PLGA-pMS)在骨组织工程中具有潜在的支架作用。但是,它们的应用受到蛋白质药物的突然释放和疏水性的阻碍,从而导致细胞黏附不良。为了克服这些缺点,我们通过在Gly-Arg-Gly-Asp-Ser-Pro-Cys(GRGDSPC)修饰的PLGA-pMS(CS)中掺入牛血清白蛋白(BSA)的壳聚糖微球(CS-MS),开发了新颖的PLGA-pMS -MS / PLGA-pMS)。 GRGDSPC用于增强多孔微球的亲水性和细胞亲和力。结果显示PLGA-pMS的尺寸为446.77±19.46μm,平均表面孔径为21.56±3.02μm,而CS-MS的尺寸为15.98±0.96μm和16.35±0.38μm(5%和10%分别由TPP准备的CS-MS。扫描电子显微镜(SEM)和共聚焦激光扫描显微镜(CLSM)显示CS-MS部分嵌入PLGA基质中,并且CS-MS的完整性得以保留。热重分析仪(TGA)也证明CS-MS已被合并到PLGA-pMS中。 CS-MS / PLGA-pMS的尺寸为454.02±16.09μm,BSA封装效率为53.19±1.67%和62.16±3.44%(分别为5%和10%TPP制备的CSMS)。 CS-MS / PLGA-pMS持续释放FITC-BSA 28天。 GRGDSPC的改性显着提高了MG-63细胞在多孔微球上的粘附力。总之,CS-MS / PLGA-pMS可能充当骨组织工程的潜在双功能支架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号